Janis M. Taube

Janis M. Taube publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Janis M. Taube sits on this spectrum.

Janis M. Taube D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Janis M. Taube sits on this spectrum.

Best Publications

• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  14371
  Citations

• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

  Dung T. Le;Jennifer N. Uram;Hao Wang;Bjarne R. Bartlett

  10084
  Citations

• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  Dung T. Le;Dung T. Le;Jennifer N. Durham;Jennifer N. Durham;Kellie N. Smith;Hao Wang

  6773
  Citations

• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

  Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  3544
  Citations

• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  Suzanne L. Topalian;Janis M. Taube;Robert A. Anders;Drew M. Pardoll

  2828
  Citations

• Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

  Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  2649
  Citations

• Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

  Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu

  2597
  Citations

• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  Janis M. Taube;Robert A. Anders;Geoffrey D. Young;Haiying Xu

  2415
  Citations

• Fulminant Myocarditis with Combination Immune Checkpoint Blockade

  Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias

  2293
  Citations

• The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

  Nicolas J. Llosa;Michael Cruise;Ada Tam;Elizabeth C. Wicks

  1612
  Citations

• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

  Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  1330
  Citations

• Neoadjuvant checkpoint blockade for cancer immunotherapy

  Suzanne L. Topalian;Janis M. Taube;Drew M. Pardoll

  966
  Citations

• Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

  Sofia Lyford-Pike;Shiwen Peng;Geoffrey D. Young;Janis M. Taube

  845
  Citations

• Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

  Kristin J. Lastwika;Kristin J. Lastwika;Willie Wilson;Qing Kay Li;Jeffrey Norris

  809
  Citations

• A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer

  David L. Rimm;Gang Han;Janis M. Taube;Eunhee S. Yi

  777
  Citations

• Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

  Evan J. Lipson;William H. Sharfman;Charles G. Drake;Ira Wollner

  653
  Citations

• Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

  Steve Lu;Julie E. Stein;David L. Rimm;Daphne W. Wang

  650
  Citations

• PD-1/PD-L1 inhibitors.

  Joel Sunshine;Janis M Taube

  620
  Citations

• Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

  Christopher M. Heaphy;Andrea P. Subhawong;Seung Mo Hong;Michael G. Goggins

  596
  Citations

• Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

  T.R. Cottrell;E.D. Thompson;P.M. Forde;J.E. Stein

  561
  Citations